A5015294531- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Immune Response and Inflammation
- Inflammasome and immune disorders
- CAR-T cell therapy research
- Quinazolinone synthesis and applications
- Pleural and Pulmonary Diseases
- Peptidase Inhibition and Analysis
- Heme Oxygenase-1 and Carbon Monoxide
- T-cell and Retrovirus Studies
- Immune Cell Function and Interaction
Imperial College London
2023-2024
Australian National University
2019-2021
Abstract Objectives Anlotinib hydrochloride (AL3818) is a novel multitarget tyrosine kinase inhibitor which has the same targets as nintedanib, an effective drug been approved for treatment of idiopathic pulmonary fibrosis. Here, we examined whether anlotinib could also attenuate bleomycin-induced fibrosis in mice and explored antifibrosis mechanism. Methods We have evaluated effect on mice. Inflammatory cytokines alveolar lavage fluid including IL-1β, IL-4, IL-6 TNF-α were determined by...
<title>Abstract</title> B-lineage acute-lymphoblastic leukemia (B-ALL) is driven by genomic lesions and distinct transcriptional programs. Both are often directly linked as most B-ALLs caused genetic at transcription factor (TF)-encoding genes. TFs largely mediate their function through gene regulatory ‘enhancer’ elements enhancer deregulation known to promote cancer initiation progression. Consecutively, enhancer-targeting drugs currently in clinical trials for advanced hematologic cancers...
Abstract PAX5 is the master transcription factor controlling B cell identity. In humans, mutations in account for 30% of acute lymphoblastic leukemia (B-ALL) cases. Investigating causal effects has however been difficult due to premature lethality Pax5 −/− mice. Here we describe a novel mouse strain with STOP mutation (Y351*) that produces truncated protein and reduction function, yet still allows some development occur. A population uncommitted multipotent CD19 + B220 − cells develops bone...
<b>Background:</b> Pirfenidone(PFD) and nintedanib(NDN), the only two drugs for IPF, which should be accurately selected in treatment, has no relevant basic research reference. <b>Objective:</b> Compare effect of PFD NDN bleomycin(BLM)-induced pulmonary fibrosis model different periods, so as to provide theoretical basis clinical application. <b>Methods:</b> The BLM periods were performed Fig1. <b>Results:</b> 1) Anti-inflammatory antioxidant capacity: inhibition rate on inflammatory cell...